Table 1.
Cardiopulmonary hemodynamics
| Parameter |
Times post injury (h) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 12 | 18 | 24 | 30 | 36 | 48 | 60 | 72 | 84 | 96 | |
| CI LI (min−1·m−2) | |||||||||||
| Vehicle | 5.8 ± 0.2 | 5.5 ± 0.3 | 5.3 ± 0.4 | 5.9 ± 0.4 | 6.1 ± 0.3 | 6.7 ± 0.5 | 7.6 ± 0.6 | 8.1 ± 1.0 | 7.4 ± 0.9 | 7.1 ± 1.7 | 8.2 ± 2.4 |
| Sulphide Treatment | 6.9 ± 0.2 | 7.1 ± 0.8 | 6.8 ± 0.5 | 6.5 ± 0.2 | 6.7 ± 0.3 | 6.4 ± 0.3 | 7.0 ± 0.6 | 7.1 ± 0.6 | 7.0 ± 0.6 | 7.7 ± 0.6 | 7.5 ± 0.7 |
| MAP (mmHg) | |||||||||||
| Vehicle | 99 ± 2 | 108 ± 3 | 104 ± 4 | 104 ± 3 | 103 ± 3 | 101 ± 3 | 105 ± 2 | 105 ± 5 | 105 ± 8 | 93 ± 3 | 88 ± 3 |
| Sulphide Treatment | 94 ± 2 | 105 ± 4 | 108 ± 4 | 104 ± 3 | 104 ± 3 | 105 ± 3 | 104 ± 3 | 104 ± 4 | 102 ± 3 | 101 ± 4 | 100 ± 5 |
| MPAP (mmHg) | |||||||||||
| Vehicle | 20.9 ± 0.7 | 25.9 ± 1.6 | 28.9 ± 1.4 | 28.9 ± 1.2 | 29.9 ± 1.4 | 29.4 ± 1.4 | 29.2 ± 1.3 | 26.3 ± 2.8 | 25.0 ± 3.0 | 23.0 ± 1.0 | 24.0 ± 2.0 |
| Sulphide Treatment | 19.9 ± 0.5 | 27.4 ± 1.3 | 27.4 ± 1.5 | 28.0 ± 1.3 | 26.8 ± 1.3 | 26.6 ± 1.6 | 28.1 ± 1.0 | 26.0 ± 1.2 | 26.6 ± 1.1 | 26.9 ± 1.3 | 27.3 ± 1.4 |
| LAP (mmHg) | |||||||||||
| Vehicle | 9.5 ± 0.7 | 9.6 ± 0.8 | 10.3 ± 1.1 | 12.0 ± 0.8 | 13.3 ± 1.1 | 13.1 ± 1.1 | 15.1 ± 1.5 | 14.0 ± 1.7 | 14.0 ± 1.0 | 13.0 ± 2.5 | 15.0 ± 3.5 |
| Sulphide Treatment | 8.0 ± 0.6 | 11.1 ± 1.4 | 11.4 ± 1.3 | 11.6 ± 0.8 | 8.0 ± 0.8* | 11.0 ± 0.6* | 12.4 ± 1.2 | 11.3 ± 1.3 | 11.0 ± 1.0 | 12.3 ± 1.2 | 9.9 ± 1.0 |
| CVP (mmHg) | |||||||||||
| Vehicle | 6.6 ± 0.9 | 9.0 ± 1.2 | 11.4 ± 2.6 | 10.1 ± 0.7 | 13.4 ± 1.6 | 11.9 ± 1.4 | 16.0 ± 5.0 | 11.3 ± 5.0 | 12.0 ± 2.1 | 13.0 ± 4.0 | 13.5 ± 2.5 |
| Sulphide Treatment | 5.6 ± 0.6 | 10.9 ± 0.7 | 9.5 ± 0.8 | 9.9 ± 0.6 | 11.1 ± 1.1* | 10.0 ± 0.8 | 9.4 ± 1.9 | 8.4 ± 1.3 | 6.3 ± 1.0* | 9.0 ± 1.0 | 9.0 ± 1.0 |
| PVRI (dyne·s−1·cm−5·m−2) | |||||||||||
| Vehicle | 150 ± 7 | 184 ± 28 | 227 ± 30 | 187 ± 20 | 183 ± 21 | 162 ± 13 | 112 ± 14 | 77 ± 7 | 136 ± 31 | 98 ± 35 | 92 ± 47 |
| Sulphide Treatment | 120 ± 7 | 146 ± 21 | 127 ± 16* | 151 ± 16 | 127 ± 11* | 135 ± 19* | 149 ± 15* | 137 ± 17* | 156 ± 16 | 135 ± 13 | 144 ± 19 |
| LVSWI (g·m−1·m−2) | |||||||||||
| Vehicle | 74 ± 4 | 61 ± 3 | 51 ± 4 | 56 ± 5 | 53 ± 2 | 57 ± 4 | 68 ± 4 | 86 ± 17 | 82 ± 17 | 67 ± 16 | 72 ± 20 |
| Sulphide Treatment | 83 ± 4 | 69 ± 7 | 71 ± 7* | 66 ± 6 | 69 ± 7* | 67 ± 6 | 69 ± 7 | 77 ± 8 | 65 ± 5 | 70 ± 4 | 60 ± 4 |
| Hct (%PCV) | |||||||||||
| Vehicle | 23.0 ± 0.8 | 25.0 ± 2.0 | 25.3 ± 2.1 | 27.3 ± 2.0 | 29.0 ± 1.5 | 27.3 ± 1.5 | 25.0 ± 1.0 | 22.0 ± 1.2 | 24.3 ± 0.9 | 22.0 ± 3.0 | 24.0 ± 3.5 |
| Sulphide Treatment | 21.8 ± 1.4 | 23.1 ± 1.6 | 23.8 ± 1.6 | 23.4 ± 1.1 | 24.5 ± 1.2* | 23.1 ± 1.5* | 24.0 ± 1.8 | 22.0 ± 1.8 | 22.0 ± 1.6 | 22.3 ± 2.1 | 23.0 ± 2.3 |
| Hb (g·mL−1) | |||||||||||
| Vehicle | 0.08 ± 0.004 | 0.09 ± 0.006 | 0.09 ± 0.007 | 0.09 ± 0.006 | 0.1 ± 0.005 | 0.09 ± 0.005 | 0.09 ± 0.005 | 0.08 ± 0.003 | 0.08 ± 0.001 | 0.08 ± 0.009 | 0.09 ± 0.01 |
| Sulphide Treatment | 0.08 ± 0.006 | 0.08 ± 0.004 | 0.08 ± 0.005 | 0.08 ± 0.005 | 0.09 ± 0.005* | 0.08 ± 0.006 | 0.08 ± 0.006 | 0.08 ± 0.007 | 0.08 ± 0.007 | 0.08 ± 0.007 | 0.08 ± 0.008 |
| FiO2 (%) | |||||||||||
| Vehicle | 0.2 ± 0.0 | 0.2 ± 0.0 | 0.3 ± 0.1 | 0.5 ± 0.1 | 0.9 ± 0.1 | 0.9 ± 0.1 | 1.0 ± 0.0 | 1.0 ± 0.0 | 1.0 ± 0.0 | 0.9 ± 0.1 | 0.7 ± 0.3 |
| Sulphide Treatment | 0.2 ± 0.0 | 0.2 ± 0.0 | 0.2 ± 0.0 | 0.4 ± 0.1 | 0.5 ± 0.1* | 0.7 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.7 ± 0.1 | 0.6 ± 0.1 | 0.5 ± 0.1 |
Values are presented as mean ± SEM.
Comparisons were made using two-way analysis of variance with a Tukey-Kramer post hoc procedure. There were only two animals in the control group from 72 to 96 h.
*
P≤ 0.05 versus control.
CI, cardiac index; CVP, central venous pressure; FiO2, fraction of inspired oxygen; Hb, haemoglobin; Hct, haematocrit; LAP, left atrial pressure; LVSWI, left venticular stroke work index; MAP, mean arterial pressure; MPAP, mean pulmonary arterial pressure; PVRI, pulmonary vascular resistance index.